It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
As knowledge of cell metabolism has advanced, glutamine has been considered an important amino acid that supplies carbon and nitrogen to fuel biosynthesis. A recent study provided a new perspective on mitochondrial glutamine metabolism, offering mechanistic insights into metabolic adaptation during tumor hypoxia, the emergence of drug resistance, and glutaminolysis-induced metabolic reprogramming and presenting metabolic strategies to target glutamine metabolism in cancer cells. In this review, we introduce the various biosynthetic and bioenergetic roles of glutamine based on the compartmentalization of glutamine metabolism to explain why cells exhibit metabolic reliance on glutamine. Additionally, we examined whether glutamine derivatives contribute to epigenetic regulation associated with tumorigenesis. In addition, in discussing glutamine transporters, we propose a metabolic target for therapeutic intervention in cancer.
Amino acid metabolism: Glutamine in healthy and cancerous cells
Insights into how the amino acid glutamine powers cellular metabolism could pave the way for effective therapeutic strategies for ‘starving’ tumor cells. Healthy cells can manufacture enough glutamine to sustain normal function, but cancerous growth creates heavier demand for this important molecule. Jung Min Han and colleagues at Yonsei University in Incheon, South Korea have reviewed the various cellular functions of glutamine, and discuss opportunities to cut off supply and thereby derail tumor proliferation. Glutamine serves as a building block both for amino acids and nucleic acids, and is also consumed during mitochondrial energy production. Several groups are exploring the feasibility of inactivating glutamine synthesis or halting cellular uptake of this amino acid as a means of depriving cancer cells of nutrients. A deeper understanding of glutamine’s metabolic functions should accelerate progress on this front.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Yonsei University, Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Incheon, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
2 Yonsei University, Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Incheon, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); Yonsei University, Department of Integrated OMICS for Biomedical Science, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)